New research casts doubt on claims that medical cannabis provides meaningful benefits for chronic pain. A scientific review of 21 clinical trials involving over 2,100 adults compared the effects of medicinal cannabis products and placebos on chronic nerve pain. Three types of products were analyzed: those with THC (the psychoactive compound), those with CBD (a non-intoxicating compound), and combination THC/CBD items.
Study Findings
Researchers found that none of the three types reduced pain more than placebo medications. Those using THC products reported increased side effects such as dizziness and drowsiness, leading some patients to withdraw from trials. The findings follow a 2025 review of over 2,500 studies that found “insufficient evidence” of cannabis benefits for most conditions, including insomnia, anxiety, post-traumatic stress disorder, Parkinson’s disease, and rheumatoid arthritis. However, cannabis has shown real benefits for chemotherapy-induced nausea, weight gain in patients with HIV/AIDS-related appetite loss, and certain severe pediatric seizure disorders.
Research Limitations and Future Directions
Clinician Winfried Häuser, lead author of the review, stated that “at present, the quality of most of the trials is too poor to draw firm conclusions.” Researchers call for larger, well-designed studies with treatment durations of at least 12 weeks that include people with comorbid physical illnesses and mental health conditions. Other research has highlighted additional risks: adolescents using high-potency cannabis face higher rates of psychotic symptoms and are more likely to develop generalized anxiety disorder. While nearly 9 in 10 adults support the use of cannabis-based medicines, the latest evidence suggests the benefits for chronic pain may be overstated.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://nypost.com/2026/01/19/health/medical-marijuanas-pain-promise-faces-new-intense-scrutiny/